BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1000 participants.

Also called NCT04666454

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04666454
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark, Norway, Sweden (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04666454. Randomized; no masking; primary purpose treatment. Start 2020-12-14 (actual); primary completion 2028-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.
Condition
Takotsubo Syndrome
Intervention (Drug)
Adenosine
Intervention (Drug)
Dipyridamole 200 mg
Intervention (Drug)
Apixaban 5 mg Oral Tablet
Intervention (Other)
Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology for takotsubo syndrome
Lead sponsor
Vastra Gotaland Region (class: other government)
Collaborator
Göteborg University (class: other)

Record details

Record id
cardio:ct-nct04666454
Content hash
a08a0e39f0b4ae3ac1e04e34cd10c6088634beedb50cff9f72911c6ea4bbdb95